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Abstract
Systemic sclerosis (SSc) is an immune-mediated
fibrotic disease affecting skin, lung and gut which are
all sites with an established microbiome. Altered
microbial flora may occur and contribute to the
initiation, progression or severity of disease. However,
dysbiosis could also be secondary to the disease or
immunosuppressive therapy. Here we consider how
lessons could be learned from gastroenterology, a
speciality where dysbiosis is strongly implicated in
disease mechanism and treatment. This could be
highly relevant to molecular pathology of skin in SSc
and could drive the inflammatory gene signature
observed in some skin biopsies.
Modern molecular techniques have allowed unprece-
dented interrogation of genomics, and this approach of-
fers insights into microbial colonisation and speciation
in the skin and other organs. This approach has been
used by Johnson et al. [1] to explore the possible role of
skin dysbiosis in systemic sclerosis (SSc). This follows a
well-trodden route of investigation that is perhaps best
delineated for the microbiome of the gastrointestinal
tract. The interface between susceptibility and environ-
ment is likely to be especially relevant in uncommon ac-
quired diseases, and a striking feature of systemic
sclerosis is early and important involvement of the skin,
gut and respiratory system. It is noteworthy that these
all represent locations where there is a well-established
microbial flora and sites for immune surveillance and
immunoregulation that could be altered by changes in
the microbiome.
In the skin, there are surprising findings in this report.
Unexpected species are present, and this might indicate
factors that trigger, amplify or promote progression of
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skin involvement. In addition, there is a clear change in
the molecular microbial signature with decreased lipo-
philic taxa and a marked increase in a wide range of
gram-negative taxa. It is notable that there is not a clear
observed association with more severe diffuse forms of
SSc which would have perhaps supported a role in pro-
gression of severity. The possible link with inflammatory
gene expression signatures in the skin raises the possibil-
ity that microbial environment might be stimulating ele-
ments of the innate or adaptive immune system relevant
to pathogenesis. However, the skin, gut and lung are also
very much altered structurally and architecturally in SSc,
and so these findings might reflect that perhaps the skin
in SSc is especially susceptible to colonisation by these
microorganisms and reflect an altered host rather than a
role in aetiopathogenesis. In addition, the pharmaco-
logical and non-drug therapies offered to all SSc cases
might impact on gut flora. Antibiotics are used regularly
to treat secondary infection and in some cases are ad-
ministered for prolonged periods.
If the significance of dysbiosis is to be proven, it is
probably helpful to look at studies within the gastro-
intestinal tract. Although relatively sparse data are avail-
able for SSc [2, 3], there is a large literature related to
other forms of GI disease. In multiple GI diseases in-
cluding irritable bowel syndrome [4], inflammatory
bowel disease [5] and liver disease [6], the putative,
causative or associated role of the gut microbiome is still
poorly understood, and more widely the association with
gut microbiota diversity and health has led to a rapidly
evolving understanding of the wide effects of diet and
disease. In fact, the implications of diet on gut micro-
biota can be profound [7], and since poor microbiota di-
versity has been demonstrated to be associated with
poor health outcomes [8], the gut microbiota appear
central in many disease processes, whether predomin-
antly due to gut-related illness or indeed in association
with both physical and mental health outcomes.
The findings in this and other studies raise intriguing
questions about cause and effect in SSc. Gut microbiota
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is affected markedly by changes in diet, and dysbiosis
has been associated with gastrointestinal features in SSc
[3]. Whether this dysbiosis is associated with changes in
gut motility and subsequent fermentation for example,
or even secondary changes in dietary preferences, or
whether it is a driver in aetiopathogenesis of SSc gut dis-
ease is not clear. In a mouse model of scleroderma asso-
ciated with anti-topoisomerase-I immunity, for example,
skin and lung fibrosis were exacerbated by perinatal
antibiotic use [8]. Could therefore scleroderma be a dis-
ease primarily driven from the gut by perturbations in
the gut microbiome at an early age? There are sugges-
tions in other immune diseases such as inflammatory
bowel disease that this may be the case [9].
In conclusion, the present study of skin microbiome is
small and requires further confirmation and study. How-
ever, it is likely that complex diseases such as SSc will
inevitably be determined in part by factors related to the
microbiome and that this may offer important potential
for symptomatic or even disease-modifying treatments
and could offer insight into the benefits reported by pa-
tients using interventions predicted to impact on skin,
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